{"id":2127,"date":"2022-03-17T09:32:00","date_gmt":"2022-03-17T09:32:00","guid":{"rendered":"https:\/\/physiciansurveypanel.com\/?p=2127"},"modified":"2026-02-24T09:43:45","modified_gmt":"2026-02-24T09:43:45","slug":"the-living-drug-car-t-cell-therapy-and-the-new-era-of-oncology-in-2022","status":"publish","type":"post","link":"https:\/\/physiciansurveypanel.com\/index.php\/2022\/03\/17\/the-living-drug-car-t-cell-therapy-and-the-new-era-of-oncology-in-2022\/","title":{"rendered":"The Living Drug: CAR T-Cell Therapy and the New Era of Oncology in 2022"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\n\t\n<\/svg>\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Reading time: 05 minutes<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Team PSP | 17\/03\/2022<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

As we move through 2022, the landscape of cancer treatment is undergoing a seismic shift. In 2020 alone, cancer claimed nearly 10 million lives globally. While conventional weapons like chemotherapy, radiation, and surgery have been our primary defense for decades, their “one-size-fits-all” approach often struggles against the complex heterogeneity of cancer cells.<\/p>\n

Enter Chimeric Antigen Receptor-T cell (CAR-T) therapy<\/strong>. No longer just a concept of the future, CAR-T has emerged as one of the most promising “living drugs” in our medical arsenal. By genetically reprogramming a patient’s own immune system to identify and incinerate malignant cells, we are seeing durable clinical responses that were once thought impossible.<\/p>\n

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"17Mar22\"\t\t\t\t\t\t\t\t\t\t\t
CAR T- CELL Therapy Process<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

How CAR T-Cell Therapy Works: Engineering an Internal Army<\/strong><\/h4>\n

CAR-T is a form of immunotherapy that turns T-cells\u2014the “soldiers” of our immune system\u2014into precision-guided missiles.<\/p>\n

    \n
  1. Recognition:<\/strong> Scientists engineer T-cells with Chimeric Antigen Receptors (CARs)<\/strong>. These are synthetic surface receptors designed to recognize specific proteins (antigens) found on the surface of cancer cells.<\/li>\n
  2. Binding:<\/strong> Once infused back into the patient, these engineered cells seek out tumor cells. The extracellular domain of the CAR binds to the tumor antigen like a key into a lock.<\/li>\n
  3. Activation:<\/strong> This binding triggers the intracellular signaling domain, activating the T-cell to launch a cytotoxic attack, destroying the cancer cell.<\/li>\n
  4. Persistence:<\/strong> Unlike traditional drugs that are metabolized and exit the body, CAR T-cells multiply into hundreds of millions and can live in the body for months, providing ongoing surveillance against relapse.<\/li>\n<\/ol>\n

    The Manufacturing Journey: From Bench to Bedside<\/strong><\/h4>\n

    Manufacturing these “living drugs” is a highly complex, customized process that requires elite coordination:<\/p>\n

      \n
    • Leukapheresis:<\/strong> The process begins by drawing the patient’s blood through a machine to isolate white blood cells (lymphocytes). The remaining blood components are returned to the patient.<\/li>\n
    • Genetic Modification:<\/strong> In specialized labs, viral vectors are used to “infect” the T-cells with the CAR gene, permanently modifying their genome to express the new receptors.<\/li>\n
    • Expansion in Bioreactors:<\/strong> Since millions of cells are needed, these engineered T-cells are grown in a bioreactor until they reach a therapeutic volume.<\/li>\n
    • Pre-conditioning:<\/strong> Before the “army” is sent back in, the patient undergoes mild chemotherapy to deplete existing lymphocytes. This clears the way and reduces “competition” for the new CAR T-cells.<\/li>\n<\/ul>\n

      2022: A Growing Investigative Pipeline<\/strong><\/h4>\n

      The medical community is currently tracking over 500 CAR T-cell therapies<\/strong> in clinical trials. While early success was found in hematologic malignancies (blood cancers) using the CD-19<\/strong> biomarker, the pipeline is expanding rapidly:<\/p>\n\n\n\n\n\n\n\n\n
      \n

      Product<\/strong><\/p>\n<\/td>\n

      		\n

      Manufacturer<\/strong><\/p>\n<\/td>\n

      		\n

      Approved Use (as of 2022)<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

      \n

      Yescarta<\/strong><\/p>\n<\/td>\n

      		\n

      Kite\/Gilead<\/p>\n<\/td>\n

      		\n

      Large B-cell lymphoma (First FDA approval in this category).<\/p>\n<\/td>\n<\/tr>\n

      \n

      Kymriah<\/strong><\/p>\n<\/td>\n

      		\n

      Novartis<\/p>\n<\/td>\n

      		\n

      ALL in children and young adults; B-cell lymphoma.<\/p>\n<\/td>\n<\/tr>\n

      \n

      Tecartus<\/strong><\/p>\n<\/td>\n

      		\n

      Kite\/Gilead<\/p>\n<\/td>\n

      		\n

      Mantle cell lymphoma (MCL) and adult ALL.<\/p>\n<\/td>\n<\/tr>\n

      \n

      Breyanzi<\/strong><\/p>\n<\/td>\n

      		\n

      Bristol Myers Squibb<\/p>\n<\/td>\n

      		\n

      Relapsed or refractory large B-cell lymphoma.<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Latest Breakthroughs:<\/strong> In late 2021, Novartis<\/strong> unveiled its T-Charge\u2122<\/strong> platform. This next-gen technology allows CAR T-cells to expand primarily inside<\/em> the patient\u2019s body rather than in a lab for weeks. This could revolutionize the implementation process, making it faster and more efficient.<\/p>\n

      Future Frontiers: Overcoming Challenges<\/strong><\/p>\n

      Despite its 90% remission rates in some trials, CAR-T still faces hurdles that researchers are tackling head-on this year:<\/p>\n

        \n
      1. Solid Tumors:<\/strong> Most current therapies target blood cancers. Trials are now aggressively pursuing targets like HER2, Meso, and EGFRvIII<\/strong> to take the fight to solid tumors like breast and lung cancer.<\/li>\n
      2. Safety (CRS):<\/strong> Cytokine Release Syndrome (CRS) remains a serious side effect. However, new prophylactic interventions and biomarker monitoring are making the treatment significantly safer in 2022.<\/li>\n
      3. Allogeneic “Off-the-Shelf” Therapy:<\/strong> Currently, most therapies are autologous<\/em> (using the patient\u2019s own cells). The next frontier is allogeneic<\/em> therapy\u2014using healthy donor cells to create “off-the-shelf” treatments that don’t require the weeks-long manufacturing wait.<\/li>\n<\/ol>\n

        Conclusion<\/strong><\/h4>\n

        The paradigm of oncology has officially shifted. CAR T-cell therapy has moved from a “last-resort” experimental treatment to a cornerstone of modern cancer care. As we expand the scope of target molecules and streamline manufacturing through platforms like T-Charge, we are moving closer to a world where “incurable” is a term of the past.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t

        \n\t\t\t\t\t

        Share<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
        \n\t\t\t\t
        \n\t\t\t\t\t
        \t\t
          \n
        • \n
          \n \n <\/i> \n <\/div>\n <\/li>\n
        • \n
          \n \n <\/i> \n <\/div>\n <\/li>\n <\/ul>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
          \n\t\t\t\t\t
          \n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

          Reading time: 05 minutes Team PSP | 17\/03\/2022 As we move through 2022, the landscape of cancer treatment is undergoing […]<\/p>\n","protected":false},"author":2,"featured_media":2128,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"_links":{"self":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/comments?post=2127"}],"version-history":[{"count":5,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2127\/revisions"}],"predecessor-version":[{"id":2135,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/posts\/2127\/revisions\/2135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/media\/2128"}],"wp:attachment":[{"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/media?parent=2127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/categories?post=2127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/physiciansurveypanel.com\/index.php\/wp-json\/wp\/v2\/tags?post=2127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}